A Nuclear Stress Pathway that Parallels Cytoplasmic Stress Granule Formation.
Cell Biology
Molecular Biology
Optical Imaging
Proteomics
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
20 Nov 2020
20 Nov 2020
Historique:
received:
12
05
2020
revised:
04
09
2020
accepted:
07
10
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Stress adaptation is exploited by cancer cells to survive and proliferate under adverse conditions. Survival pathways induced by stress are thus highly promising therapeutic targets. One key pathway involves formation of cytoplasmic stress granules, which regulate the location, stability, and translation of specific mRNAs. Here, we describe a transcriptional stress response that is triggered by similar stressors and characterized by accumulation of RepoMan (cell division cycle associated 2) at nuclear stress foci (nucSF). Formation of these structures is reversible, and they are distinct from known nuclear organelles and stress bodies. Immunofluorescence analysis revealed accumulation of heterochromatic markers, and increased association of RepoMan with the adenylate cyclase 2 (ADCY2) gene locus in stressed cells accompanied reduced levels of ADCY2 mRNA and protein. Quantitative comparison of the RepoMan interactome in stressed vs. unstressed cells identified condensin II as a nucSF factor, suggesting their functional association in the establishment and/or maintenance of these facultative heterochromatic domains.
Identifiants
pubmed: 33134894
doi: 10.1016/j.isci.2020.101664
pii: S2589-0042(20)30856-7
pmc: PMC7586129
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101664Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Cell Sci. 2017 Mar 1;130(5):927-937
pubmed: 28096475
Oncotarget. 2017 Mar 21;8(12):19768-19779
pubmed: 28423619
Biochim Biophys Acta Mol Basis Dis. 2017 Apr;1863(4):884-895
pubmed: 28095315
Nat Rev Mol Cell Biol. 2016 Jul;17(7):399-412
pubmed: 27075410
Mol Cell. 2012 Jul 27;47(2):242-52
pubmed: 22727621
PLoS One. 2007 Jul 04;2(7):e594
pubmed: 17611626
Nat Methods. 2019 Sep;16(9):866-869
pubmed: 31451765
PLoS Genet. 2018 Jul 12;14(7):e1007393
pubmed: 30001329
BMC Cancer. 2019 Jun 13;19(1):576
pubmed: 31196027
J Cell Biol. 2006 Feb 27;172(5):679-92
pubmed: 16492807
Dev Cell. 2011 Aug 16;21(2):328-42
pubmed: 21820363
PLoS One. 2013;8(2):e56381
pubmed: 23418564
Nat Commun. 2017 Jan 16;8:14048
pubmed: 28091603
Mol Biol Cell. 2016 Apr 15;27(8):1188-96
pubmed: 26912792
J Cell Sci. 2018 Oct 5;131(19):
pubmed: 30185525
J Cell Biol. 2008 Oct 20;183(2):223-39
pubmed: 18936248
Cell. 2016 Dec 15;167(7):1803-1813.e12
pubmed: 27984728
Curr Biol. 2011 May 10;21(9):766-73
pubmed: 21514157
Curr Biol. 2020 Feb 24;30(4):698-707.e6
pubmed: 31956030
Elife. 2016 Sep 07;5:
pubmed: 27602576
Curr Biol. 2013 Jun 17;23(12):1136-43
pubmed: 23746640
EMBO Rep. 2016 Oct;17(10):1374-1395
pubmed: 27629041
J Cell Biol. 2004 Oct 11;167(1):27-33
pubmed: 15479734
Oncogene. 2014 Mar 13;33(11):1359-66
pubmed: 23524579
Oncogene. 2005 Feb 24;24(9):1533-41
pubmed: 15592497
Cancers (Basel). 2014 Feb 26;6(1):436-58
pubmed: 24577242
Mol Cell Proteomics. 2013 May;12(5):1468-86
pubmed: 23362328
Curr Opin Cell Biol. 2014 Jun;28:76-83
pubmed: 24704702
Methods. 2020 Mar 30;:
pubmed: 32240773
Nat Cell Biol. 2006 Oct;8(10):1133-42
pubmed: 16998479
Mol Biol Cell. 2007 Jul;18(7):2603-18
pubmed: 17475769
Proteomics. 2012 May;12(10):1623-38
pubmed: 22610586
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6769-74
pubmed: 10359787
J Cell Biol. 2012 Jul 23;198(2):173-83
pubmed: 22801782
Biochim Biophys Acta. 2015 Jul;1849(7):861-70
pubmed: 25482014
Cancer Cell. 2004 May;5(5):429-41
pubmed: 15144951
Sci Rep. 2017 Dec 14;7(1):17556
pubmed: 29242629
Biochem Biophys Res Commun. 2012 Jul 13;423(4):763-9
pubmed: 22705549
J Neurooncol. 2016 Apr;127(2):253-60
pubmed: 26732083
Curr Biol. 2010 Mar 9;20(5):387-96
pubmed: 20188555
Toxicol Lett. 2011 Nov 30;207(2):149-58
pubmed: 21925251
Mol Cell. 2008 Sep 5;31(5):722-36
pubmed: 18775331
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Mol Ther. 2016 Feb;24(1):156-65
pubmed: 26373347
Elife. 2015 Feb 26;4:
pubmed: 25719440
Leukemia. 2010 Apr;24(4):679-86
pubmed: 20130602
Nat Commun. 2019 Apr 29;10(1):1930
pubmed: 31036827
Lab Invest. 1998 Feb;78(2):165-74
pubmed: 9484714
J Cell Biol. 2013 Jul 22;202(2):261-76
pubmed: 23878275
Adv Exp Med Biol. 2014;773:401-14
pubmed: 24563358
Nat Protoc. 2019 Mar;14(3):832-863
pubmed: 30778205
Curr Cancer Drug Targets. 2001 May;1(1):73-83
pubmed: 12188893
Trends Cell Biol. 2016 Sep;26(9):668-679
pubmed: 27289443
J Clin Oncol. 2013 Feb 10;31(5):608-15
pubmed: 23319690
Cancer Cell Int. 2010 Apr 29;10:12
pubmed: 20429927
Cell. 2003 Jun 13;113(6):703-16
pubmed: 12809602
Microsc Microanal. 2013 Jun;19(3):617-28
pubmed: 23552615
Mol Cell Biol. 2011 Mar;31(5):1098-108
pubmed: 21173160
Traffic. 2014 Oct;15(10):1179-93
pubmed: 24990581
J Cell Biol. 2015 Mar 30;208(7):913-29
pubmed: 25800057
J Cell Sci. 2007 Aug 15;120(Pt 16):2774-84
pubmed: 17652158
J Cell Biol. 2000 Dec 11;151(6):1257-68
pubmed: 11121440